İrEm Yavuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
İrEm Yavuz has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Elçin Ulusoy
Alaca State Hospıtal, Department of Physical Medicine and Rehabilitation , Alaca
1 shared publication - Gizem Cengiz
Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Turkey
1 shared publication - Hasan Kara
Erciyes Üniversitesi Tıp Fakültesi
1 shared publication - Hüseyin Kaplan
Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Erciyes University Faculty of Medicine, Kayseri, Turkiye
1 shared publication - İsA Cüce
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Turkey
1 shared publication - Mehmet Kirnap
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Türkiye
1 shared publication
Latest Publications
- 15 March 2026
- Published by Bozok Tip Dergisi in Bozok Tıp Dergisi
- Vol. 16 (1) , 48-55
Retrospective Analysis of Patients Prescribed Pregabalin and Gabapentin in Physical Medicine, Rehabilitation, and Rheumatology Outpatient Clinics
Purpose: This study aims to investigate the use of gabapentinoids (gabapentin and pregabalin) in the management of pain in musculoskeletal diseases, and to evaluate the demographic characteristics, comorbidities and reasons for prescribing these drugs.Materials and Methods: Between January 2023 and July 2024, 615 patients aged ≥18 years who applied to Erciyes University Faculty of Medicine- Physical Medicine and Rehabilitation and Rheumatology outpatient clinic and received gabapentinoid treatment were retrospectively analyzed. Demographic characteristics, comorbidities, laboratory values [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and creatinine], doses of gabapentinoid drugs, and reasons for prescription were obtained from the patient record system.Results: The mean age of the patients included in the study was 59.8±12.6 years and 78.2% were female. The most common comorbidities in all patients were hypertension (51.3%), rheumatological diseases (36.5%) and diabetes mellitus (30.3%), respectively. The most common rheumatological diseases were rheumatoid arthritis (40.6%) and spondyloarthritis (39.3%). The rate of rheumatological comorbidity was statistically significantly higher in the pregabalin group (60.5%) compared to the gabapentin group (32.8%) (p
- 15 March 2026
- Published by Bozok Tip Dergisi in Bozok Tıp Dergisi
- Vol. 16 (1) , 48-55
Retrospective Analysis of Patients Prescribed Pregabalin and Gabapentin in Physical Medicine, Rehabilitation, and Rheumatology Outpatient Clinics
Purpose: This study aims to investigate the use of gabapentinoids (gabapentin and pregabalin) in the management of pain in musculoskeletal diseases, and to evaluate the demographic characteristics, comorbidities and reasons for prescribing these drugs.Materials and Methods: Between January 2023 and July 2024, 615 patients aged ≥18 years who applied to Erciyes University Faculty of Medicine- Physical Medicine and Rehabilitation and Rheumatology outpatient clinic and received gabapentinoid treatment were retrospectively analyzed. Demographic characteristics, comorbidities, laboratory values [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and creatinine], doses of gabapentinoid drugs, and reasons for prescription were obtained from the patient record system.Results: The mean age of the patients included in the study was 59.8±12.6 years and 78.2% were female. The most common comorbidities in all patients were hypertension (51.3%), rheumatological diseases (36.5%) and diabetes mellitus (30.3%), respectively. The most common rheumatological diseases were rheumatoid arthritis (40.6%) and spondyloarthritis (39.3%). The rate of rheumatological comorbidity was statistically significantly higher in the pregabalin group (60.5%) compared to the gabapentin group (32.8%) (p